Compare Old Dominion Freight Line Inc (ODFL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Old Dominion Freight Line Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Old Dominion Freight Line Inc trades at $183.23 (market cap $36.42B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.5× Old Dominion Freight Line Inc's market cap, and Old Dominion Freight Line Inc pays a 0.66% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Old Dominion Freight Line Inc for 76 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ODFL | VRTX | |
|---|---|---|
Market Cap | $36.42B | $128.16B |
Volume | 1,668,932 | 806,603 |
Sector | Industrials | Health |
52-Week High | $248.73 | $557.96 |
52-Week Low | $126.29 | $407.37 |
Typical Hold Time | 76 Days | 120 Days |
Enterprise Value | $36.15B | $122.29B |
Dividend Yield | 0.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Old Dominion Freight Line (ODFL) trades at $181.65, up 2.04% today, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 19.44% net margins and 24.82% ROE, though revenue declined to $5.5B in 2025. Recent news highlights a 4.9% general rate increase effective October 5, 2026, aimed at offsetting operating costs while supporting service investments.
ODFL presents a mixed outlook with Wall Street's $230.93 consensus target suggesting 27% upside, yet technical indicators remain bearish. The stock's premium valuation (P/E 33.77) requires sustained earnings growth, while competitive pressures and freight demand volatility pose risks. Institutional buying and oversold technical conditions may support near-term recovery potential.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
